Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting from the only global scientific conference focused on the challenging and ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...

Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...

ETHealthworld.com brings latest generic versions news, views and updates from all top sources for the Indian Health industry.

In this week’s Health Matters newsletter, Ramya Kannan discusses the Nobel Prize in Physiology or Medicine, Indian ...

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the ...

The generic companies that will manufacture and supply Lenacapavir to 120 countries are Dr. Reddy’s, Emcure, Eva Pharma, ...

US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...

Africa is contributing to groundbreaking data from the PURPOSE 2 study, which explores twice-yearly lenacapavir for HIV ...